Liverpool COVID-19 Drug Interactions (www.covid19-druginteractions.org)

利物浦 COVID-19 药物相互作用 (www.covid19-druginteractions.org)

• 批准号: MR/V020498/1
• 负责人: Saye Khoo
• 金额: $ 8.43万
• 依托单位: University of Liverpool
• 依托单位国家: 英国
• 项目类别: Research Grant
• 财政年份: 2020
• 资助国家: 英国
• 起止时间: 2020 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=MR%2FV020498%2F1
• 关键词: Liverpool; COVID; 19; Drug; Interactions

The Liverpool University Drug Interactions group has over twenty years' experience in developing prescribing support resources in infectious diseases, demonstrated by our world-renowned HIV and Hepatitis drug interaction websites (www.hiv-druginteractions.org and www.hep-druginteractions.org) and associated Apps. In 2019, these websites had over 50,000 unique monthly visitors searching for >4.5 million interactions. Our websites are recommended in over 30 international treatment guidelines and many national guidelines. In response to the COVID-19 pandemic and to address the pressing need for prescribing support for studies and clinical situations where experimental COVID-19 therapies are being used, we have developed a static drug interactions website (www.covid19-druginteractions.org) providing information on the likelihood of interactions between the experimental agents and commonly prescribed co-medications. We now have to move to develop a fully interactive and searchable website resource with an associated App. The website will be constantly updated and populated with the latest information on experimental therapies with guidance given to clinicians for managing complex patients.

利物浦大学药物相互作用小组在开发传染病处方支持资源方面拥有二十多年的经验，我们世界著名的艾滋病毒和肝炎药物相互作用网站（www.hiv-druginteractions.org和www.hep-druginteractions.org）和相关应用程序就证明了这一点。2019年，这些网站每月有超过50，000名独立访问者搜索超过450万次互动。我们的网站被30多个国际治疗指南和许多国家指南推荐。为应对COVID-19大流行，并满足对使用实验性COVID-19疗法的研究和临床情况的处方支持的迫切需求，我们开发了一个静态药物相互作用网站（www.covid19-druginteractions.org），提供有关实验性药物与常用处方合并用药之间相互作用可能性的信息。我们现在必须着手开发一个完全互动和可搜索的网站资源，并配备一个相关的应用程序。该网站将不断更新，并提供有关实验疗法的最新信息，为临床医生管理复杂患者提供指导。

项目成果

Dolutegravir pharmacokinetics during co-administration with either artemether/lumefantrine or artesunate/amodiaquine.

多替拉韦与蒿甲醚/本芴醇或青蒿琥酯/阿莫地喹联合给药期间的药代动力学。

• DOI: 10.1093/jac/dkab022
• 发表时间: 2021
• 期刊: The Journal of antimicrobial chemotherapy
• 作者: Kawuma AN

Polypharmacy-associated risk of hospitalisation among people ageing with and without HIV: an observational study.

• DOI: 10.1016/s2666-7568(21)00206-3
• 发表时间: 2021-10
• 期刊: The lancet. Healthy longevity
• 作者: Justice AC;Gordon KS;Romero J;Edelman EJ;Garcia BJ;Jones P;Khoo S;Lo Re V 3rd;Rentsch CT;Tate JP;Tseng A;Womack J;Jacobson D
• 通讯作者: Jacobson D

Pharmacokinetics and Drug-Drug Interactions of Long-Acting Intramuscular Cabotegravir and Rilpivirine.

• DOI: 10.1007/s40262-021-01005-1
• 发表时间: 2021-07
• 期刊: Clinical pharmacokinetics
• 影响因子: 4.5
• 作者: Hodge D;Back DJ;Gibbons S;Khoo SH;Marzolini C
• 通讯作者: Marzolini C

Response to "A Case Report of Safe Coadministration of Amioradone With Short-Term Treatment Nirmatrelvir-Ritonavir".

对“胺碘酮与短期治疗尼尔马韦-利托那韦安全联合用药的病例报告”的回应。

• DOI: 10.1002/cpt.2809
• 发表时间: 2023
• 期刊: Clinical pharmacology and therapeutics
• 影响因子: 6.7
• 作者: Marzolini C

Associations between plasma nucleoside reverse transcriptase inhibitors concentrations and cognitive function in people with HIV.

• DOI: 10.1371/journal.pone.0253861
• 发表时间: 2021
• 期刊: PloS one
• 影响因子: 3.7
• 作者: De Francesco D;Wang X;Dickinson L;Underwood J;Bagkeris E;Babalis DS;Mallon PWG;Post FA;Vera JH;Sachikonye M;Williams I;Khoo S;Sabin CA;Winston A;Boffito M;Pharmacokinetic and Clinical Observations in PeoPle Over fiftY (POPPY) study
• 通讯作者: Pharmacokinetic and Clinical Observations in PeoPle Over fiftY (POPPY) study